Darzalex can now be used in combination with two standard of care regimens —lenalidomide and dexamethasone, or bortezomib and dexamethasone — for the treatment of patients with multiple myeloma who have received at least one prior therapy, according to a company news release.
The FDA first approved the drug in November 2015 and the medication earned breakthrough therapy designation for the new indication in July 2016.
More articles on supply chain:
Novo Nordisk, Sanofi to battle for sales with new combination diabetes drugs: 4 takeaways
Sanofi earns FDA approval for type 2 diabetes treatment
FDA approves Novo Nordisk’s new combination therapy for type 2 diabetes
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
